



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Debra M. Eckert, David C. Chan, Vladimir Malashkevich, Peter A. Carr and
Peter S. Kim

Application No.: 09/746,742 Group Art Unit: 1627

Filed: December 21, 2000 Examiner: Celsa, B.M.

Confirmation No.: 8580

For: Inhibitors of HIV Membrane Fusion

RECEIVED

APR 02 2003

TECH CENTER 1600/2900

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202	
on <u>3-24-03</u>	<u>Jerine Crump</u>
Date	Signature
<u>Jerine Crump</u>	
Typed or printed name of person signing certificate	

REPLY TO RESTRICTION REQUIREMENT AND
SECOND PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
P.O. Box 2327
Arlington, VA 22202

Sir:

Responsive to the Restriction Requirement dated September 24, 2002, the claims of Group I (Claims 1-15, 38 and 39) drawn to a fusion protein comprising a soluble trimeric form and a portion of HIV gp41 are elected for prosecution. Applicant reserves the right to file a continuing application or take such other appropriate action as deemed necessary to protect the non-elected inventions. Applicant does not hereby abandon or waive any rights in the non-elected inventions.

Responsive to the requirement for an election of species for searching purposes, Applicant hereby elects SEQ ID NO: 4 as the species. Claim 9 contains SEQ ID NO: 4 as a member of the Markush group of the claim.